Mustang Bio Shares Are Trading Higher After the Company on Monday Announced Safety and Efficacy Data From the Complete Waldenstrom Macroglobulinemia Cohort of Its Phase 1/2 Clinical Trial of MB-106, Showing an Overall Response Rate of 90% With One...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.